Recent Updates
Recently added Catalysts
PHAT Negative Sentiment

PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Phathom Pharmaceuticals on behalf of the company's stockholders, focusing on potential violations of federal securities laws. The inquiry highlights a past incident where the company reported trace levels of a nitrosamine in its drug product, resulting in significant stock price decline and delayed product launches. Investors who have suffered losses are encouraged to contact the law firm for more information.
Price reaction · baseline $11.76 (2023-05-26 close) · hit after-hours · 1 other PHAT headline(s) in the window, move may be shared
day 0 close · peak
-3.1%

Market Sentiment Analysis

CONCERNS & RISKS

  • Investigation is being conducted into potential securities law violations by Phathom Pharmaceuticals.
  • Past incident where stock price fell 28% after announcing nitrosamine contamination in vonoprazan.
  • Planned delays in product launches due to required additional testing and regulatory measures.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+166%
120-day peak, hindsight
Typical move
4.5%
average across 7 past catalysts
Cash runway
~283 mo
Minimal dilution risk
Lead asset
Vonoprazan
Phase 3 · Erosive Esophagitis

Full Press Release Details

NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) (NASDAQ: PHAT) on behalf of Phathom stockholders. Our investigation concerns whether Phathom has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On August 2, 2022, before market hours, Phathom issued a press release entitled “Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates” which announced that “we detected trace levels of a nitrosamine in vonoprazan drug product in our post-approval testing as we prepared for commercial launch.” Further, the press release announced that “[t]he Company is working with the FDA and plans to obtain approval of and implement an additional test method, specification, including a proposed acceptable intake limit, and additional controls to address this impurity prior to releasing our first vonoprazan-based products to the market.” Finally, the Company announced that “[t]hese additional activities will result in a delay of the planned VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK product launches.”
On this news, Phathom’s stock price fell $2.61 per share, or 28%, to close at $6.46 per share on August 2, 2022.
If you purchased or otherwise acquired Phathom shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.

Frequently Asked Questions

What is Bragar Eagel & Squire investigating?

They are investigating potential claims against Phathom Pharmaceuticals for possible violations of federal securities laws.

What caused Phathom's stock price to drop?

Phathom's stock fell 28% after announcing trace levels of a nitrosamine in vonoprazan.

How can I participate in the investigation?

You can contact Bragar Eagel & Squire via email or phone to learn more.

What impacts did the press release announce?

The company announced delays in launching vonoprazan-based products due to impurity issues.

What is the cost to claim potential losses?

There is no cost or obligation to individuals interested in learning more about their claims.

Last updated: May 27, 2023